Axogen logo
AXGNAxogen
Trade AXGN now
Axogen primary media

About Axogen

Axogen (NASDAQ:AXGN) specializes in innovative solutions for peripheral nerve injuries. The company is deeply involved in the development and commercialization of surgical nerve repair solutions that aim to restore functionality and improve the quality of life for patients suffering from physical damage or trauma to peripheral nerves. This ambitious objective is pursued through a diverse portfolio of products including Avance® Nerve Graft, AxoGuard® Nerve Connector, and AxoGuard® Nerve Protector, among others, each designed to address different aspects of nerve repair and protection. Axogen's projects range from research and development in nerve regeneration to clinical studies aimed at advancing the field of peripheral nerve repair. The company's overarching goal is to continue pioneering in the nerve repair space, striving to bring innovative and effective treatments to patients worldwide.

What is AXGN known for?

Snapshot

Public US
Ownership
2002
Year founded
427
Employees
Alachua, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Produtos e/ou serviços de Axogen

  • Avance Nerve Graft, a biologically based extracellular matrix for peripheral nerve reconstruction.
  • Axoguard Nerve Connector, a coaptation aid for tensionless repair of severed nerves.
  • Axoguard Nerve Protector, designed to protect and isolate the nerve and reduce the formation of neuromas.
  • Axoguard Nerve Cap, specifically developed to prevent neuroma formation at the nerve endings.
  • Acroval Neurosensory & Motor Testing System, provides comprehensive diagnostic information for evaluating peripheral nerve injuries.
  • Axogen's Education and Training services, aimed at surgeons and medical personnel to advance the understanding and application of nerve repair solutions.

equipe executiva do Axogen

  • Mr. Michael D. DalePresident, CEO & Director
  • Mr. Marc A. BeganExecutive VP, General Counsel & Chief Compliance Officer
  • Mr. Jens Schroeder KempChief Marketing Officer
  • Mr. Erick DeVinneyChief Innovation Officer
  • Ms. Lindsey Hartley CPAChief Financial Officer
  • Mr. Craig A. SwandalVice President of Operations
  • Mr. Harold D. Tamayo M.B.A.Vice President of Finance & Investor Relations
  • Ms. Doris QuackenbushVice President of Sales
  • Dr. Ivica Ducic M.D., Ph.D.Chief Medical Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.